Nitika Pharmaceutical Specialties aims to establish a state-of-the-art manufacturing facility for commercial-scale production of 14 complex excipients
The Technology Development Board (TDB), Department of Science and Technology (DST), has extended financial support to Nitika Pharmaceutical Specialties, Nagpur, for their project titled Manufacture of Complex Excipients.
Through this project, Nitika Pharmaceutical Specialties aims to establish a state-of-the-art manufacturing facility for commercial-scale production of 14 complex excipients that cater to advanced pharmaceutical applications. These products will be developed in line with the Quality by Design (QbD) framework, ensuring precision in parameters like surface area, particle size, and stability to meet international standards.
The project is also aligned with the Government of India’s Production Linked Incentive (PLI) scheme for pharmaceuticals, under which M/s Nitika has been selected as a beneficiary under Group C – MSME (Pharmaceuticals). TDB’s support complements the broader national mission of fostering indigenous manufacturing, reducing import dependency, and expanding India’s export potential in high-value pharmaceutical components.
Speaking on the occasion, Rajesh Kumar Pathak, Secretary, TDB, said: “India’s pharmaceutical strength must be matched with domestic resilience in critical inputs like excipients. TDB is pleased to support Nitika’s forward-looking project that strengthens India’s position not just as a pharmacy of the world, but also as a maker of world-class excipients. This initiative will boost both Atmanirbhar Bharat and India’s capacity to support global health.”
The leadership of Nitika Pharmaceutical Specialties said, “This support from TDB reinforces our commitment to building world-class excipient solutions in India. With advanced infrastructure and a science-led approach, we aim to reduce our country’s dependency on imported excipients and emerge as a global leader in pharmaceutical ingredients developed and manufactured domestically.”
PIB
